Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy

Fig. 3

Comparison of DFS(c) and OS(d) curves between patients with different groups (PLR<135, NLR>135). c: There were no significant differences in DFS between the high PLR group and the low PLR group [HR 0.962 (95% CI, 0.038, 0.150); p = 0.876]; d: There were no significant differences in OS between the high PLR group and the low PLR group [HR 0.778 (95% CI,0.251, 0.721); p = 0.454]

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us